IQVHIGH SIGNALFINANCIAL10-K

IQVIA delivered exceptional 42% revenue growth to $9.7B while significantly expanding debt by $3.1B, suggesting major acquisition activity or aggressive expansion.

The massive revenue jump combined with substantial debt increase indicates IQVIA likely completed a major acquisition or series of acquisitions during the period. While the growth is impressive, investors should scrutinize whether the debt-financed expansion will generate sustainable returns and monitor integration risks from rapid scaling.

Comparing 2026-02-17 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

IQVIA's financials show dramatic expansion across all metrics, with revenue surging 42% to $9.7B while total debt increased 42% to $10.3B, indicating significant debt-funded growth likely through acquisitions. The company maintained financial flexibility with cash growing to $2.0B, though total liabilities expanded 12% to $23.3B. Interestingly, R&D expenses declined 42% despite massive revenue growth, which may signal improved efficiency or integration of acquired assets, though investors should monitor whether this impacts long-term innovation capabilities.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-42.4%
$5.8M$3.3M

R&D spending cut 42.4% — could signal cost discipline or concerning reduction in innovation investment.

Total Debt
Balance Sheet
+42.2%
$7.2B$10.3B

Debt increased 42.2% — substantial leverage increase; assess whether deployed for growth or covering losses.

Revenue
P&L
+41.6%
$6.9B$9.7B

Strong top-line growth of 41.6% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+19.9%
$7.0B$8.3B

Current liabilities rose 19.9% — increased short-term obligations, watch current ratio.

Cash & Equivalents
Balance Sheet
+16.3%
$1.7B$2.0B

Cash grew 16.3% — improving liquidity position supports investment and shareholder returns.

Total Liabilities
Balance Sheet
+11.9%
$20.8B$23.3B

Liabilities increased 11.9% — monitor debt-to-equity ratio and interest coverage.

Total Assets
Balance Sheet
+11.3%
$26.9B$29.9B

Asset base grew 11.3% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-13
ADDED
As of February 6, 2026, there were approximately 169.7 million shares of the registrant s common stock outstanding.
In addition, we may not achieve the expected benefits of our reorganized business segment structure.
We are committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry.
We have one of the largest and most comprehensive collections of healthcare information in the world spanning sales, prescription, promotional and social media data, as well as medical claims, electronic medical records, and genomics data, including more than 1.2 billion comprehensive, longitudinal, unique non-identified patient records.
Longitudinal analysis across disparate datasets is enabled via internally developed fully compliant tokenization engines.
+7 more — sign up free →
REMOVED
As of February 5, 2025, there were approximately 176.1 million shares of the registrant s common stock outstanding.
We are committed to using artificial intelligence ("AI") responsibly, ensuring that our AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety.
We have one of the largest and most comprehensive collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales, prescription and promotional data, medical claims, electronic medical records, genomics, and social media.
The portion of this addressable opportunity that was outsourced in 2024, based on our estimates, was approximately $73 billion.
Real-World Evidence and connected health: Total addressable market of approximately $85 billion in 2024 that consists of tightly coupled life sciences and healthcare markets.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →